Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2018-03-15 Annual Report
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
ANNUAL REPORT
Annual Report FY 2017
2018-03-15 English
Other Report or Announcement
Share Issue/Capital Change Classification · 95% confidence The document explicitly states it is a "Prospectus" dated March 6, 2018, and details an offer for sale of American Depositary Shares (ADSs) and ordinary shares. It includes standard prospectus sections like 'Risk Factors', 'Use of Proceeds', 'Management's Discussion and Analysis', 'Plan of Distribution', and warnings from the SEC and other regulatory bodies regarding approval. This structure is characteristic of a registration statement or prospectus filed with the SEC to offer securities to the public. Since it is a prospectus detailing an offering, the most appropriate classification among the provided options is related to capital raising or financing activities, which aligns best with 'Capital/Financing Update' (CAP). While a prospectus often accompanies a registration statement (like an S-1), 'CAP' covers updates on fundraising and financing activities, which is the core purpose of this document.
2018-03-08 English
Other Report or Announcement
Report Publication Announcement Classification · 98% confidence The document is very short (2261 characters) and explicitly states that it is a 'Delay the publication of a report' notification. Crucially, it mentions 'Attached hereto is a report on *Final Prospectus*' and lists the attached file name 'XTL_Biopharmaceuticals_Ltd_isa.pdf'. According to Rule 2 ('THE "MENU VS MEAL" RULE'), when a document announces the publication of another report (like a Prospectus, which is often related to capital raising or offering documents) rather than containing the full content itself, it should be classified as a Report Publication Announcement (RPA). A Final Prospectus itself would typically fall under Capital/Financing Update (CAP) or potentially Regulatory Filing (RNS), but this document is merely the announcement of its publication.
2018-03-08 English
424B3
Regulatory Filings
2018-03-07 English
Regulatory Filings 2018
Regulatory Filings
2018-03-07 English
Regulatory Filings 2018
Regulatory Filings
2018-03-02 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.